Acadia Pharmaceuticals | ACAD - Assets



Acadia Pharmaceuticals reported $1.23B in Assets for its fiscal quarter ending in June of 2025.


Assets Change Date
Acadia Pharmaceuticals USD 1.23B 93.19M Jun/2025
ALKERMES USD 2.25B 170.83M Jun/2025
Alnylam Pharmaceuticals USD 4.57B 352.21M Jun/2025
Biogen USD 28.33B 297.1M Jun/2025
BioMarin Pharmaceutical USD 7.46B 309.33M Jun/2025
Bristol-Myers Squibb USD 94.68B 2.25B Jun/2025
Corcept Therapeutics USD 801.72M 44.73M Jun/2025
Cytokinetics USD 1.23B 38.42M Jun/2025
Eisai JPY 1.41T 23.07B Jun/2025
Eli Lilly USD 100.92B 11.53B Jun/2025
Incyte USD 5.82B 71.99M Jun/2025
J&J USD 193.67B 13.57B Mar/2025
Moderna USD 12.01B 694M Jun/2025
Neurocrine Biosciences USD 3.89B 202.1M Jun/2025
Pfizer USD 206.1B 1.93B Jun/2025
Prothena USD 399.07M 148.04M Jun/2025
PTC Therapeutics USD 2.63B 21.23M Jun/2025
Sarepta Therapeutics USD 3.68B 214.43M Jun/2025
Ultragenyx Pharmaceutical USD 1.31B 5.66M Jun/2025
Vertex Pharmaceuticals USD 24.04B 1.16B Jun/2025